SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ANDRX-Reaffirm Outperform Recommendation-Gruntal Research
An SI Board Since November 1996
Posts SubjectMarks Bans Symbol
23 0 0 ADRX
Emcee:  PAUL ROBERT ST. ONGE Type:  Unmoderated
Introduction Market Data Compact
Andrx received a Reaffirm Outperform Recommendation from Gruntal Research today 11/4/96, as Andrx increased third quarter revenues better than expected, up 86%. Andrx received an important Patent for Cardizem CD and adds new candidate to pipeline. Net loss estimates have been revised downward for 4th qtr, from (-.23) to (-.10) and 1996 total down from (-.50) to now (-.35). Four new formulations have been added to their list. New patent for Cardizem CD creates barriers to potential competitors and could stregthen legal action against Hoechst
Marion Roussel. The result of the patent also indicates the potential competion will have to avoid patent infrindgement of both (HMR) as well as Andrx. Andrx has also established several cororate allainces with Watson, Mylan, Ivax, and Sepracor with additional annoucements and alliances expected early next year. Revenue estimates from Andrx drug destribution operations have been revised up to $85 million for the year about $10 million higher than analyst expectation, with expected growth of 50% through the year 2000. Two drugs awaiting approval, 18 canidates in the pipeline with a value of $4.1 billion. from innovator firms. 18 month price target $26, which I consider extremely conservative. Comments, questions, others that follow?
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
23 James: Individual Investor has listed Andrx (ADRX) in their (Hot Stocks) sectioPAUL ROBERT ST. ONGE-6/4/1997
22 Excellent news Paul, Looks as if ADRX is actively trying to diversify their piJames Silverman-12/20/1996
21 Andrx is involved in world-wide licensing agreement with ASTA Medica AG- announPAUL ROBERT ST. ONGE-12/20/1996
20 I know quite a few people who have tried to do the same and failed, even with vPAUL ROBERT ST. ONGE-12/19/1996
19 Paul, I placed a bid today trying to cut the spread, no luck filling it. IJames Silverman-12/19/1996
18 I do not have any contacts at Andrx, although it would be nice. Andrx is a screPAUL ROBERT ST. ONGE-12/18/1996
17 Thanks Paul, I saw the news. Big positive. The bigger story will be if a simJames Silverman-12/18/1996
16 James: I just wanted to pass along this message: Andrx Corp. announced today thPAUL ROBERT ST. ONGE-12/18/1996
15 Paul Robert St. Onge wrote: It appears to be that Andrx will share at least halJames Silverman-11/14/1996
14 It appears to be that Andrx will share at least half the royalties, and I wouldPAUL ROBERT ST. ONGE-11/14/1996
13 Paul In regards to the ADRX/SEPR JV, its an interesting one although difficult James Silverman-11/14/1996
12 I believe that the "ANDA's" that will be filed in 1997, a few mayPAUL ROBERT ST. ONGE-11/14/1996
11 >Conservatively speaking the potential revenue totals will most likely >nJames Silverman-11/13/1996
10 Andrx is positioned to take advantage of major controlled release patent expiraPAUL ROBERT ST. ONGE-11/13/1996
9 I agree with your comments in regards to Biovail. I just feel it wise to gaugeJames Silverman-11/13/1996
8 It was wise of you to do further research regarding Andrx, as far as Biovail, IPAUL ROBERT ST. ONGE-11/13/1996
7 Paul, I've received the ADRX investment packet. Going to have Biovail sendJames Silverman-11/13/1996
6 Additional drugs are forth coming, including some that have long been touted byPAUL ROBERT ST. ONGE-11/8/1996
5 Paul, My experiences with drug delivery firms has been terrible. KV, ETHCY, GNJames Silverman-11/8/1996
4 Hoechst has filed patent claims, to what appears to be more a non-patent issuePAUL ROBERT ST. ONGE-11/7/1996
3 Paul, Why do you expect an early approval, given Hoechst has filed patent claiJames Silverman-11/7/1996
2 Zack's Investment Research-Wall Street Recommendation has also upgraded indPAUL ROBERT ST. ONGE-11/7/1996
1 What is the price of the stock at this timeMike Carlson-11/7/1996
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News